

```
ring nodes:
    1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

chain bonds:
    1-10 8-13 14-21

ring bonds:
    1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 14-15 14-19 15-16 16-17 17-18 18-19


exact/norm bonds:
    8-13

exact bonds:
    1-10 14-21

normalized bonds:
    1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 14-15 14-19 15-16 16-17 17-18 18-19

isolated ring systems:
    containing 1: 7: 14:
```

Match level:
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom 21:CLASS



```
ring nodes:
    1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

chain bonds:
    1-10 8-13 13-22 14-21

ring bonds:
    1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 14-15 14-19 15-16 16-17 17-18 18-19

exact/norm bonds:
    8-13 13-22

exact bonds:
    1-10 14-21

normalized bonds:
    1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 14-15 14-19 15-16 16-17 17-18 18-19

isolated ring systems:
    containing 1: 7: 14:
```

Match level:
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom
12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom 21:CLASS 22:CLASS

* * *	* *	* *	* *	* Welcome to STN International * * * * * * * * *
NEWS	1			Web Page URLs for STN Seminar Schedule - N. America
NEWS	2			"Ask CAS" for self-help around the clock
NEWS	3	SEP	09	CA/CAplus records now contain indexing from 1907 to the
				present
NEWS	4	DEC	80	INPADOC: Legal Status data reloaded
NEWS	5	SEP	29	DISSABS now available on STN
NEWS	6	OCT		PCTFULL: Two new display fields added
NEWS	7	OCT	21	BIOSIS file reloaded and enhanced
NEWS	8	OCT		BIOSIS file segment of TOXCENTER reloaded and enhanced
NEWS	9	NOA	24	MSDS-CCOHS file reloaded
NEWS	10	DEC	80	CABA reloaded with left truncation
NEWS	11	DEC	80	IMS file names changed
NEWS	12	DEC	09	Experimental property data collected by CAS now available in REGISTRY
NEWS	13	DEC	09	STN Entry Date available for display in REGISTRY and CA/CAplus
NEWS	14	DEC	17	DGENE: Two new display fields added
NEWS	15	DEC	18	BIOTECHNO no longer updated
NEWS	16	DEC	19	CROPU no longer updated; subscriber discount no longer
				available
NEWS	<u>17</u>	DEC	22	Additional INPI reactions and pre-1907 documents added to CAS
				databases
NEWS	18	DEC	22	IFIPAT/IFIUDB/IFICDB reloaded with new data and search fields
NEWS		DEC	22	ABI-INFORM now available on STN
NEWS	20	JAN	27	Source of Registration (SR) information in REGISTRY updated
				and searchable
NEWS	21	JAN	27	A new search aid, the Company Name Thesaurus, available in
				CA/CAplus
NEWS	22	FEB	05	German (DE) application and patent publication number format
				changes
NEWS		MAR		MEDLINE and LMEDLINE reloaded
NEWS			03	
NEWS	25	MAR	03	FRANCEPAT now available on STN
NEWS	EXP	RESS		RCH 5 CURRENT WINDOWS VERSION IS V7.00A, CURRENT
				CINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
				O CURRENT DISCOVER FILE IS DATED 3 MARCH 2004
NEWS				N Operating Hours Plus Help Desk Availability
NEWS				neral Internet Information
NEWS			_	lcome Banner and News Items
NEWS		1E		rect Dial and Telecommunication Network Access to STN
NEWS	WWW		CAS	S World Wide Web Site (general information)
Enter	NEW	: fo	llow	ed by the item number or name to see news on that

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 23:56:52 ON 17 MAR 2004

=> file reg
COST IN U.S. DOLLARS

SINCE FILE TOTAL ENTRY SESSION

FULL ESTIMATED COST 0.21 0.21

FILE 'REGISTRY' ENTERED AT 23:56:57 ON 17 MAR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 16 MAR 2004 HIGHEST RN 663883-43-0 DICTIONARY FILE UPDATES: 16 MAR 2004 HIGHEST RN 663883-43-0

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter <u>HELP PROP</u> at an arrow prompt in the file or refer to the file summary sheet on the web at: http://www.cas.org/ONLINE/DBSS/registryss.html

=>

L1 STRUCTURE UPLOADED

=>

L2 STRUCTURE UPLOADED

=> 12

L2 IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system. For a list of commands available to you in the current file, enter "HELP COMMANDS" at an arrow prompt (=>).

=> d 11

L1 HAS NO ANSWERS

L1

STR

=> s 13

SAMPLE SEARCH INITIATED 23:59:02 FILE 'REGISTRY' SAMPLE SCREEN SEARCH COMPLETED - 1109 TO ITERATE

90.2% PROCESSED 1000 ITERATIONS INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED) SEARCH TIME: 00.00.01 0 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**

PROJECTED ITERATIONS:

20183 TO 24177

PROJECTED ANSWERS: 0 TO

L3 0 SEA SSS SAM L1

=> s 11 full

THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 155.00 U.S. DOLLARS DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y
FULL SEARCH INITIATED 23:59:07 FILE 'REGISTRY'


FULL SCREEN SEARCH COMPLETED - 23221 TO ITERATE


100.0% PROCESSED 23221 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.03

L4 0 SEA SSS FUL L1

=> L5 STRUCTURE UPLOADED

=> d 15 L5 HAS NO ANSWERS L5 ST





MODE AT	TLT	20 T E	o :	
NSPEC	IS	R	AT	1
NSPEC	IS	R ·	AT	2
NSPEC	IS	R	AT	3
NSPEC	IS	R	AT	4
NSPEC	IS	R	AT	5
NSPEC	IS	R	AT	6
NSPEC	IS	R	AT	7

39 ANSWERS

```
ΑT
       IS R
                      8
NSPEC
      IS R
               AT
NSPEC
       IS R
                 ΑT
                    10
NSPEC
       IS R
                 AT
NSPEC
                     11
       IS R
NSPEC
                 AT
                     12
NSPEC
       IS R
                 AT
                     13
       IS R
NSPEC
                 AT
                     14
      IS R
NSPEC
                 AT
                    15
NSPEC
      IS R
                 AΤ
                    16
NSPEC
      IS R
                 AT
                    17
NSPEC
       IS R
                 AT
                    18
NSPEC
       IS R
                 AΤ
                     19
NSPEC
       IS C
                 AT
                     20
DEFAULT MLEVEL IS ATOM
MLEVEL IS CLASS AT 20
DEFAULT ECLEVEL IS LIMITED
```

GRAPH ATTRIBUTES:

RSPEC I

NUMBER OF NODES IS 20

STEREO ATTRIBUTES: NONE

=> s 15

SAMPLE SEARCH INITIATED 00:01:49 FILE 'REGISTRY' SAMPLE SCREEN SEARCH COMPLETED - 1403 TO ITERATE

1000 ITERATIONS 71.3% PROCESSED INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 25814 TO 30306 PROJECTED ANSWERS: 651 TO


L6 39 SEA SSS SAM L5

=> L7STRUCTURE UPLOADED

=> d 17

L7 HAS NO ANSWERS

L7 STR



AT 20 IS C NSPEC NSPEC IS C AT 21 DEFAULT MLEVEL IS ATOM MLEVEL IS CLASS AT 20 21 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RSPEC I

NUMBER OF NODES IS

STEREO ATTRIBUTES: NONE

=> s 17

SAMPLE SEARCH INITIATED 00:03:04 FILE 'REGISTRY' SAMPLE SCREEN SEARCH COMPLETED -8 TO ITERATE

100.0% PROCESSED

8 ITERATIONS

3 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: **COMPLETE** ONLINE BATCH **COMPLETE**

3 SEA SSS SAM L7

PROJECTED ITERATIONS: PROJECTED ANSWERS:

8 TO 329 3 TO 163

=> s 17 full

L8

L9

THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 155.00 U.S. DOLLARS DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y FULL SEARCH INITIATED 00:03:08 FILE 'REGISTRY' FULL SCREEN SEARCH COMPLETED -

100.0% PROCESSED

73 ITERATIONS

22 ANSWERS

314.41

SEARCH TIME: 00.00.01

22 SEA SSS FUL L7

=> file hcaplus

COST IN U.S. DOLLARS

SINCE FILE TOTAL ENTRY SESSION

314.20

FULL ESTIMATED COST

FILE 'HCAPLUS' ENTERED AT 00:03:11 ON 18 MAR 2004 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 17 Mar 2004 VOL 140 ISS 12

FILE LAST UPDATED: 16 Mar 2004 (20040316/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 19

L10

4 L9

=> d 110, ibib abs fhitstr, 1-4

L10 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Citing Text References

ACCESSION NUMBER:

2003:57902 HCAPLUS

DOCUMENT NUMBER:

138:117662

TITLE:

Use of NK-1 receptor antagonists for the treatment of

brain, spinal or nerve injury

INVENTOR(S):

Hoffmann, Torsten; Nimmo, Alan John; Sleight, Andrew;

Vankan, Pierre; Vink, Robert

PATENT ASSIGNEE(S):

F. Hoffmann-La Roche A.-G., Switz.

SOURCE:

PCT Int. Appl., 36 pp.

the second second

CODEN: PIXXD2 Patent

DOCUMENT TYPE: LANGUAGE:

English

DAMELY ACC NUM CO

endiren

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO. KIND DATE						APPLICATION NO. DATE										
								-								
WO 2003006016			A2 20030123			W	200	02-E	P732	3	2002	0703				
WO 2003006016			A3 20030731								_					
W:	ΑE,	AG,	AL,	AM,	AT,	AU,	ΑZ,	BA,	BB,	BG,	BR,	BY,	BZ,	CA,	CH,	CN,
	CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	ES,	FI,	GB,	GD,	GE,	GH,
	GM,	HR,	ΗU,	ID,	ΙL,	IN,	IS,	JP,	KE,	KG,	KP,	KR,	ΚZ,	LC,	LK,	LR,
	LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MZ,	NO,	NZ,	PH,	PL,
	PT,	RO,	RU,	SD,	SE,	SG,	SI,	SK,	SL,	TJ,	TM,	TR,	TT,	TZ,	UA,	UG,
	UZ,	VN,	YU,	ZA,	ZW,	AM,	ΑZ,	BY,	KG,	KΖ,	MD,	RU,	ТJ,	TM		
RW:	GH,	GM,	KE,	LS,	MW,	MZ,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	AT,	BE,	BG,
	CH,	CY,	CZ,	DE,	DK,	EE,	ES,	FI,	FR,	GB,	GR,	IE,	IT,	LU,	MC,	NL,
	PT,	SE,	SK,	TR,	BF,	ВJ,	CF,	CG,	CI,	CM,	GA,	GN,	GQ,	GW,	ML,	MR,
	NE,	SN,	TD,	TG												

US 2003083345

A1 20030501

<u>US 2002-187587</u> 20020702 EP 2001-116812 A 20010710

PRIORITY APPLN. INFO.:

OTHER SOURCE(S):

MARPAT 138:117662

The invention discloses the use of an NK-1 receptor antagonist (Markush included), e.g. N-(3,5-bis-trifluoromethylbenzyl)-N-methyl-6-(4-methylpiperazin-1-yl)-4-o-tolylnicotinamide, optionally in combination with a magnesium salt, for the treatment and/or prevention of brain, spinal or nerve injury. The invention also relates to pharmaceutical compns. comprising one or more such NK-1 receptor antagonists, optionally in combination with a magnesium salt, and a pharmaceutically acceptable excipient, for the treatment and/or prevention of brain, spinal or nerve injury.

IT 391674-73-0

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(NK-1 receptor antagonist for treatment of brain, spinal or nerve injury)

RN 391674-73-0 HCAPLUS

CN Benzeneacetamide, N,α,α-trimethyl-N-[4-(2-methylphenyl)-6-(4oxido-4-morpholinyl)-3-pyridinyl]-3,5-bis(trifluoromethyl)- (9CI) (CA
INDEX NAME)

L10 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Citing Text References

ACCESSION NUMBER:

2002:832668 HCAPLUS

DOCUMENT NUMBER:

137:337901

TITLE:

Preparation and use of amides as NK-1 receptor antagonists against benign prostatic hyperplasia

INVENTOR(S):

Buser, Susanne; Ford, Anthony P. D. W.; Hoffmann, Torsten; Lenz, Barbara; Sleight, Andrew John; Vankan,

Pierre

PATENT ASSIGNEE(S):

F. Hoffmann-La Roche A.-G., Switz.

SOURCE:

GΙ

PCT Int. Appl., 45 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATEN						ND DATE APPLICATION NO. DATE											
	-	- -															
WO 200	20854	58	A.	A2 20021031				W	20	02-E	P108	5	20020202				
WO 200	WO 2002085458 A					A3 20031030											
W	W: AE, AG, AL					AU,	AZ,	BA,	BB,	BG,	BR,	BY,	ΒZ,	CA,	CH,	CN,	
	CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	ES,	FΙ,	GB,	GD,	GE,	GH,	
	GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	ΚE,	KG,	ΚP,	KR,	KZ,	LC,	LK,	LR,	
	LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MZ,	NO,	NZ,	PH,	PL,	
	PT,	RO,	RU,	SD,	SE,	SG,	SI,	SK,	SL,	ТJ,	TM,	TR,	TT,	TZ,	UA,	UG,	
	·UZ,	VN,	YU,	ZA,	ZW,	AM,	ΑZ,	BY,	KG,	ΚZ,	MD,	RU,	ТJ,	TM			
RV	V: GH,	GM,	KE,	LS,	MW,	MZ,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	ÄΤ,	BE,	CH,	
	CY,	DE,	DK,	ES,	FI,	FR,	GB,	GR,	ΙE,	IT,	LU,	MC,	NL,	PT,	SE,	TR,	
	BF,	ВJ,	CF,	CG,	CI,	CM,	GΑ,	GN,	GQ,	GW,	ML,	MR,	ΝE,	SN,	TD,	TG	
EP 138	<u> 35577</u>		A:					EP 2002-719751									
R	AT,	BE,	CH,	DE,	DK,	ES,	FR,	GB,	GR,	IT,	LI,	LU,	NL,	SE,	MC,	PT,	
	ΙE,	SI,	LT,	LV,	FI,	RO,	MK,	CY,	AL,	TR							
US 200	US 2003004157 P							U:	3 20	02-7	1570		2002	0208			
PRIORITY A	IORITY APPLN. INFO.:]	EP 2001-109853 A				Α	20010423				
				WO 2002-EP1085 W 20020						0202							
OTHER SOURCE	CE(S):			MARPAT 137:337901													

$$\begin{array}{c|c}
R^{1} \\
R \\
R^{3} \\
R^{3}
\end{array}$$

$$\begin{array}{c}
R^{2} \\
R^{21}
\end{array}$$

$$\begin{array}{c}
R^{21} \\
R^{3}
\end{array}$$

Use of an NK-1 receptor antagonist for the treatment or prevention of AΒ benign prostatic hyperplasia (BPH) is claimed. The preferred NK-1 receptor antagonists are compds. of the general formula [I; R = H, alkyl, alkoxy, halo, CF3; R1 = H, halo; RR1 = CH:CHCH:CH; R2, R21 = H , halo , CF3, alkyl, alkoxy, cyano; R2R21 = CH:CHCH:CH, optionally substituted by 1-2 alkyl, halo, alkoxy; R3 = H, alkyl; R3R3C = cycloalkyl; R4 = H, N(R5)2, NR5(CH2)nOH, cyclic tertiary amine, etc.; X = CONR5, (CH2)pO, NR5(CH2)p, etc.; R5 = H, cycloalkyl, Ph, PhCH2, alkyl; n = 0-4; p = 1-3]. Preferred compds. are 2-(3,5-bis-trifluoromethyl-phenyl)-N-methyl-N-(6morpholin-4-yl-4-o-tolyl-pyridin-3-yl)isobutyramide, 3-(3,5-bistrifluoromethyl-phenyl)-N-methyl-N-[6-(4-methyl-piperazin-1-yl)-4-o-tolylpyridin-3-yl]isobutyramide, 2-(3,5-bis-trifluoromethyl-phenyl)-N-[6-(1,1dioxo-1λ6-thiomorpholin-4-yl)-4-o-tolyl-pyridin-3-yl]-Nmethylisobutyramide, and 2-(3,5-bis-trifluoromethylphenyl)-N-[6-(1,1-dioxo-1λ6-thiomorpholin-4-yl)-4-(4-fluoro-2-methyl-phenyl)-pyridin-3-yl]-N-methylisobutyramide. Thus, 2-[3,5-bis(trifluoromethyl)phenyl]-N-methyl-N-(6-thiomorpholin-4-yl-4-o-tolylpyridin-3-yl)isobutyramide (prepn. given) oxone were stirred 2 days at room temp. to give 2-(3,5-bistrifluoromethylphenyl)-N-[6-(1,1-dioxo-1\lambda6-thiomorpholin-4-yl)-4-otolylpyridin-3-yl]-N-methylisobutyramide. 2-(3,5-Bistrifluoromethylphenyl)-N-methyl-N-methyl-N-(6-morpholin-4-yl-4-otolylpyridin-3-yl)isobutyramide at 60 mg/kg/day orally in dogs reduced prostate wt. by 58% after 39 wk.


IT 391674-73-0

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(prepn. and use of amides as NK-1 receptor antagonists against benign prostatic hyperplasia)

RN 391674-73-0 HCAPLUS

CN Benzeneacetamide, N,α,α-trimethyl-N-[4-(2-methylphenyl)-6-(4-oxido-4-morpholinyl)-3-pyridinyl]-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)



L10 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2004 ACS on STN

Full Citing
Text References
ACCESSION NUMBER:

2002:157739 HCAPLUS

DOCUMENT NUMBER: 136:216651

TITLE: Preparation of 4-phenylpyridines as neurokinin-1

receptor antagonists

INVENTOR(S):

Godel, Thierry; Hoffmann, Torsten; Schnider, Patrick;

Stadler, Heinz

PATENT ASSIGNEE(S):

F. Hoffmann-La Roche A.-G., Switz.

SOURCE:

GΙ

PCT Int. Appl., 108 pp. CODEN: PIXXD2

Patent

DOCUMENT TYPE: LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

	PATENT NO.				KI	KIND DATE APPLICATION NO. DATE														
	WO	2002	0163	24	A1 20020228					WO 2001-EP8686							20010727			
		W:	ΑE,	AG,	AL,	AM,	ΑT,	AU,	ΑZ,	BA	, B	ВВ,	BG,	BR,	BY,	BZ,	CA,	CH,	CN,	
			CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ	, E	EC,	EE,	ES,	FI,	GB,	GD,	GE,	GH,	
			GM,	HR,	HU,	ID,	IL,	IN,	IS,	JΡ	, K	Œ,	KG,	KP,	KR,	ΚZ,	LC,	LK,	LR,	
			LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK	, M	ĺΝ,	MW,	MX,	MZ,	NO,	NZ,	PL,	PT,	
			RO,	RU,	SD,	SE,	SG,	SI,	SK,	\mathtt{SL}	, Т	IJ,	TM,	TR,	TT,	TZ,	UA,	UG,	UZ,	
			VN,	YU,	ZA,	ZW,	AM,	ΑZ,	BY,	KG	, K	ζZ,	MD,	RU,	ТJ,	TM				
		RW:	GH,	GM,	KE,	LS,	MW,	MZ,	SD,	\mathtt{SL}	, s	SZ,	TZ,	UG,	ZW,	ΑT,	ΒE,	CH,	CY,	
			DE,	DK,	ES,	FI,	FR,	GB,	GR,	ΙE	, I	T,	LU,	MC,	ΝL,	PT,	SE,	TR,	BF,	
			ВJ,	CF,	CG,	CI,	CM,	GΑ,	GN,	GQ	, G	₩,	ML,	MR,	ΝE,	SN,	TD,	TG		
	AU	2002	0121	18	A.	5	2002	0304		:	AU	200	2-12	2118		2001	0727			
•	EP	1309	<u> 559</u>						EP 2001-980219						2001	0727				
		R:	ΑT,	BE,	CH,	DE,	DK,	ES,	FR,	GB	, G	R,	IT,	LI,	LU,	NL,	SE,	MC,	PT,	
			ΙE,	SI,	LT,	LV,	FI,	RO,	MK,	CY	, A	L,	TR							
	BR	2001	0131	73	Α		2003	0624			BR	200	1-13	3173		2001	0727			
		2004									JP	200	2-52	2120	<u>0</u>	20010727				
	US	2002	0400	40	A.	1	2002	0404	•		US	200	1-92	2206	5	20010803				
	NO	2003	0006	32	Α		2003	0207			NO	200	3-63	32		2003	0207			
PRIO	PRIORITY APPLN. INFO.:									EP	200	0 - 1	1700	03	Α	2000	8080			
,	WO 2001-EP8686 W 20010727																			
OTHE	THER SOURCE(S): MARPAT 136:216651																			

$$\begin{array}{c|c}
 & & & & & & & & & & & & & & & & \\
R^2 & & & & & & & & & & & & & & \\
R^2 & & & & & & & & & & & & & \\
R^3 & & & & & & & & & & & & \\
R^4 & & & & & & & & & & & \\
R^4 & & & & & & & & & & & \\
R^4 & & & & & & & & & & \\
R^4 & & & & & & & & & \\
R^4 & & & & & & & & & \\
R^4 & & & & & & & & & \\
R^4 & & & & & & & & \\
R^4 & & & & & & & & \\
R^4 & & & & & & & & \\
R^4 & & & & & & & & \\
R^4 & & & & & & & & \\
R^4 & & & & & & & \\
R^4 & & & & & & & \\
R^4 & & & & & & & \\
R^4 & & & & & & & \\
R^4 & & & & & & & \\
R^4 & & & & & & \\
R^4 & & & & & & & \\
R^4 & & & & & \\
R^4 & & & & & & \\
R^4 & & & & \\
R^4 & & & & & \\
R^4 & & & & \\
R^4 & & & & & \\
R^4 & & & & & \\
R^4 & & & \\
R^4 & & & \\
R^4 & & & \\
R^4 & & & \\
R^4$$

The title compds. [I; R = H, halo; $R1 = (C \equiv C) mR11$, (CR' = CR'') mR11AΒ (wherein R11 = halo, CN, aryl, etc.; R', R'' = H, OH, alkyl, etc.); R2 = H, alkyl, alkoxy, halo, CF3; R3, R31 = H, alkyl or form together with the C atom to which they are attached a cycloalkyl group; R4, R41 = H, halo, CF3, alkyl, alkoxy; R and R2 or R4 and R41 may be together CH=CHCH=CH, optionally substituted by one or two substituents selected from alkyl, halo or alkoxy; X = CONR8, (CH2)pO, (CH2)pNR8, NR8CO, NR8(CH2)p (wherein R8 = H, alkyl); n = 1-2; m = 0-4; p = 1-2] which are antagonists of the Neurokinin 1 (NK-1, substance P) receptor, and therefore useful in the treatment of diseases, related to this receptor, were prepd. and formulated. E.g., a multi-step synthesis of I [R = H; R1 = N(OH)CH2CH2OH;

ľ

R2 = Me; R3, R31 = Me; R4 = 3-CF3; R41 = 5-CF3; X = NMeCO] which showed pKi of 9.29 in human NK1 receptor assay, was given.


IT 391674-73-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of 4-phenylpyridines as neurokinin-1 receptor antagonists)

RN 391674-73-0 HCAPLUS

CN Benzeneacetamide, N,α,α -trimethyl-N-[4-(2-methylphenyl)-6-(4-oxido-4-morpholinyl)-3-pyridinyl]-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT:

THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 4 OF 4 HCAPLUS COPYRIGHT 2004 ACS on STN

5

Full Citing Text References

ACCESSION NUMBER:

2002:72051 HCAPLUS

DOCUMENT NUMBER:

136:118387

TITLE:

Preparation of N-oxides as NK1 receptor antagonist

prodrugs of 4-phenylpyridine derivatives

INVENTOR(S):

Hoffmann, Torsten; Poli, Sonia Maria; Schnider,

Patrick; Sleight, Andrew

PATENT ASSIGNEE(S):

F. Hoffmann-La Roche A.-G., Switz.

SOURCE:

PCT Int. Appl., 43 pp. CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIN	D DATE		· A l	PPLI	CATIO	ои ис	ο.	DATE	•		
WO 2002006236	 5 Δ1	20020	20020124 WO 2001-EP7850 2001070									
	nem							_			CIT	CDT
	AG, AL, A		-	-		-			•	•	•	•
. CO, C	CR, CU, (CZ, DE,	DK, DM,	DZ,	EC,	EE,	ES,	FI,	GB,	GD,	GE,	GH,
GM, I	HR, HU,	ID, IL,	IN, IS,	JP,	KE,	KG,	KΡ,	KR,	ΚZ,	LC,	LK,	LR,
LS, I	LT, LU, i	LV, MA,	MD, MG,	MK,	MN,	MW,	MX,	MZ,	NO,	NZ,	PL,	PT,
RO, I	RU, SD, S	SE, SG,	SI, SK,	SL,	TJ,	TM,	TR,	TT,	TZ,	UA,	UG,	UZ,
VN,	U, ZA, S	ZW, AM,	AZ, BY,	KG,	ΚZ,	MD,	RU,	ТJ,	TM			
RW: GH, O	SM, KE, I	LS, MW,	MZ, SD,	SL,	SZ,	TZ,	UG,	ZW,	AT,	BE,	CH,	CY,
DE, I	OK, ES, 1	FI, FR,	GB, GR,	ΙE,	IT,	LU,	MC,	NL,	PT,	SE,	TR,	BF,
ВЈ, (CF, CG, C	CI, CM,	GA, GN,	GW,	ML,	MR,	ΝE,	SN,	TD,	TG		
EP 1303490	A1	20030	423	E	P 200	01 √94	1947	5	2001	709		
R: AT, E	BE, CH, I	DE, DK,	ES, FR,	GB,	GR,	IT,	LI,	LU,	NL,	SE,	MC,	PT,
IE, S	SI, LT, 1	LV, FI,	RO, MK,	CY,	ΑL,	TR						
BR 2001012475 A 20030729 BR 2001-12475 20010709												
JP 2004504301	JP 2002-512140 20010709											
US 2002045642	A1	20020	418	U	3 200	01-90	04059	9	2001	712		
US 6593472 B2 20030715												
HR 2003000003 A1 20030228 HR 2003-3 20030102												

US 2003149039	A 1	20030807	US 2003-33754	3	20030107
NO 2003000154	Α	20030113	NO 2003-154		20030113
US 2004014793	A1	20040122	US 2003-61627	6	20030709
US 2004048901	A1	20040311	US 2003-64589	<u>5</u>	20030821
PRIORITY APPLN. INFO.	. :		EP 2000-115287	Α	20000714
			WO 2001-EP7850	W	20010709
			US 2001-904059	A3	20010712
•			US 2003-337543	Α3	20030107

OTHER SOURCE(S):

MARPAT 136:118387

GΙ

$$(R1)_{n}$$

$$(R2)_{n}$$

$$(R2)_{n}$$

$$(R2)_{n}$$

$$(R3)_{n}$$

$$(R2)_{n}$$

$$(R3)_{n}$$

AB The prepn. is described for N-oxides (I) wherein R is hydrogen, lower alkyl, lower alkoxy, or trifluoromethyl; R1 is hydrogen or halogen; or R and R1 may be together with the ring carbon atoms to which they are attached -CH=CH-CH=CH-; R2 and R2' are independently from each other hydrogen, halogen, trifluoromethyl, lower alkoxy or cyano; or R2 and R2' may be together -CH=CH-CH+CH-, optionally substituted by one or two substituents selected from lower alkyl or lower alkoxy; R3, R3' are independently from each other hydrogen, lower alkyl or cycloalkyl; R4, R4' are independently from each other -(CH2)mOR6 or lower alkyl; or R4 and R4' form together with the N-atom to which they are attached a cyclic tertiary amine with substituent R5 chosen from hydrogen, hydroxy, lower alkyl, -lower alkoxy, -(CH2)mOH, -COOR3, -CON(R3)2,-N(R3)CO-lower alkyl or -C(O)R3; R6 is hydrogen, lower alkyl or phenyl; X is -C(O)N(R6)-, -N(R6)C(0) -, -(CH2)mO - or -O(CH2)m -; n is 0, 1, 2, 3 or 4 and; m is 1, 2, or 3; and to their pharmaceutically acceptable acid addn. salts. These compds. may be uses as prodrugs for the treatment or prevention of illnesses, related to the NK1 receptor. Thus, 2-[3,5bis(trifluoromethyl)phenyl]-N-methyl-N-[6-(4-oxymorpholin-4-yl)-4-otolylpyridin-3-yllisobutyramide (II) and related compds. were prepd. in multistep procedures.

IT 391674-73-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of aminopyridine N-oxides as NK1 receptor antagonist prodrugs of 4-phenylpyridine derivs.)

RN <u>39</u>1674-73-0 HCAPLUS

CN Benzeneacetamide, N,α,α-trimethyl-N-[4-(2-methylphenyl)-6-(4oxido-4-morpholinyl)-3-pyridinyl]-3,5-bis(trifluoromethyl)- (9CI) (CA
INDEX NAME)

REFERENCE COUNT:

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> file caold		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
•	ENTRY	SESSION
FULL ESTIMATED COST	21.39	335.80
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-2.77	-2.77

FILE 'CAOLD' ENTERED AT 00:04:00 ON 18 MAR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

3

FILE COVERS 1907-1966 FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

This file supports REG1stRY for direct browsing and searching of all substance data from the REGISTRY file. Enter $\underline{\text{HELP FIRST}}$ for more information.

=> d his

(FILE 'HOME' ENTERED AT 23:56:52 ON 17 MAR 2004)

	FILE	'REGI	STI	RY'	ENTE	RED	\mathtt{AT}	23	:56:5	7 ON	17	MAR	2004
L1			S	rru	CTURE	UP	LOAI	ŒD					
L2			S	TRU	CTURE	UP	LOAI	ŒD					
L3		0	S	L1									
L4		0	S	L1	FULL								
L5			S	TRU	CTURE	UP	LOAI	ŒD					
L6		39	S	L5									
L7			S	rru	CTURE	UP	LOAI	DED					
Ŀ8		3	S	L7									
L9		22	S	L7	FULL								

FILE 'HCAPLUS' ENTERED AT 00:03:11 ON 18 MAR 2004 L10 4 S L9

FILE 'CAOLD' ENTERED AT 00:04:00 ON 18 MAR 2004

=> s 19

L11 0 L9

=> log y

COST IN U.S. DOLLARS SINCE FILE TOTAL ENTRY SESSION

FULL ESTIMATED COST 0.42 336.22

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)
SINCE FILE TOTAL
ENTRY SESSION
CA SUBSCRIBER PRICE
0.00 -2.77

STN INTERNATIONAL LOGOFF AT 00:04:08 ON 18 MAR 2004